Back to results
US 11,596,603 B2Granted
Dry powder formulations for inhalation
AssigneeVectura Limited
InventorKambiz Yadidi
Life of this patent
Estimating the term…
Abstract
A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
Claims24
A dry powder composition comprising dry particles that comprise acetylsalicylic acid or a pharmaceutically acceptable salt thereof,
- wherein the dry particles have a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm,
- wherein the composition further comprises one or more phospholipids in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the composition,
- wherein the acetylsalicylic acid or a pharmaceutically acceptable salt thereof is in an amount greater than 50% (w/w) of the composition, and
- wherein the MMAD varies less than about 10% after the dry powder composition is stored at 30° C. at 65% relative humidity for about 4 weeks or,
- wherein the MMAD varies less than about 10% after the dry powder composition is stored at 50° C. at 75% relative humidity for about 2 weeks, or
- wherein the MMAD varies less than about 10% after the dry powder composition is stored at 50° C. for about 5 days.
3 more elements
Dependencies are inferred from the claim text.